Navigation Links
Pharmos Corporation Reports 2008 First Quarter Results
Date:5/8/2008

mune disorders. The Company's lead product, dextofisopam, is being studied in a Phase 2b clinical trial in patients with IBS. Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033) and was very well tolerated. A second program in Phase 2a involves a clinical trial of our NanoEmulsion cream drug delivery system to deliver the NSAID diclofenac topically in patients suffering from osteoarthritic knee pain. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds, especially CB2 receptor-selective (CB2-selective) agonists. PRS-639,058, the leading CB2-selective agonist, has demonstrated promising preclinical data in neuropathic pain. Various other CB2-selective compounds from Pharmos' pipeline are in preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders.

Safe Harbor Statement

Statements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.

(Tables attached)

PHARMOS CORPORATION

(Unaudited)

Consolidated Statements
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pharmos Issues Letter to Shareholders
2. Pharmos Corporation Reports 2007 Third Quarter Results
3. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
4. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
5. Pharmos Corporation Announces Board and Management Changes
6. Pharmos Corporation Completes Initial Closing of Private Placement
7. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. BioElectronics Corporation Announces Singapore and Malaysia Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 Yuma Regional ... and complementary therapies brings comprehensive cancer care to ... Yuma Regional Cancer Center has officially opened. A ... program includes services such as open, semi-private and ... American Cancer Society Resource Center, hematology, rehabilitation center, ...
(Date:7/30/2014)... July 30, 2014 Researchers often use ... biology, but such devices can do much more ... As such, researchers have looked to patterned assemblies ... metabolic engineering to characterize – and potentially ... devices are envisioned to recreate animal and human ...
(Date:7/30/2014)... , July 30, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that ... RXI-109, for the reduction of recurrence of ... has been initiated. Logo - ...
(Date:7/30/2014)... Diego, CA (PRWEB) July 30, 2014 ... contract from the U.S. Environmental Protection Agency (EPA). ... expertise in developmental toxicity models, including tests designed ... neuron formation and the formation of connections between ... Inhibition of neurodifferentiation and synapse formation by environmental ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... 10 Varian, Inc.,(NasdaqGS: VARI) announced the release ... applications involving liquid-state samples. The,OneNMR Probe product line ... a single probe rather than switching probes for,different ... and,research chemists performing a broad range of common ...
... TOKYO, and REDWOOD CITY, Calif., March 10, Otsuka ... PDLI ) today announced the closing of ... PDL,s,rights to IV Busulfex(R) (busulfan), including trademarks, patents,intellectual ... inventory,value., IV Busulfex is an oncologic product ...
... (Amex: PTN ) announced today the completion ... novel, long-acting natriuretic peptide,receptor A (NPRA) agonist under ... (CHF). The Phase I trial was a,randomized, double-blind, ... volunteers who received the medication or placebo,subcutaneously. The ...
Cached Biology Technology:Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses 2Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 2Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 3Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 4Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 3Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 4
(Date:7/30/2014)... team of biologists, led by Clemson University associate professor ... pest that will pave the way for novel anti-fouling ... for medical and industrial applications. , The team,s findings, ... the last larval stage of barnacles that attaches to ... possibly polymeric material that acts as an underwater heavy-duty ...
(Date:7/30/2014)... today announced an across-the-board increase in Impact Factors ... InCites Journal Citation Reports (Thomson Reuters, 2014) show ... , Essays in Biochemistry , Biochemical ... all received increases in their Impact Factors. The ... published by Portland Press Limited. , 2014 Impact ...
(Date:7/30/2014)... professor from Wayne State University,s College of Engineering ... Science Foundation for the project, "Nanoparticle-directed synthesis of ... Science Foundation, nanotechnology is the creation and utilization ... properties and functions. A major bottleneck in scaling ... that connect different functional materials into one device. ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... mean lighting more bush fires, ecologists have proposed. ... threatened by encroaching woodland that is destroying their habitat, ... and Stanford University (USA) has shown. "Broad-headed snakes ... km of Sydney, and those small communities are fast ...
... Over the past few years, honey bee keepers have experienced ... honey bee populations, causing some growers of fruits, nuts and ... the future. A new study published in the Annals ... bees, which are not affected by CCD, may serve as ...
... team of scientists from the National Institute of Oceanography ... expedition on research vessel Polarstern. The cooperative project Lohafex ... But it has dampened hopes on the potential of ... dioxide (CO 2 ) and thus mitigate global warming. ...
Cached Biology News:Australia's most endangered snake might need burning 2Wild bees can be effective pollinators 2Lohafex provides new insights on plankton ecology 2Lohafex provides new insights on plankton ecology 3Lohafex provides new insights on plankton ecology 4
APO-BrdU™ TUNEL Assay Kit *with Alexa Fluor® 488 anti-BrdU* *60 assays*...
The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
Recombinant Rat PTX2/SAP...
Request Info...
Biology Products: